Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients

Indaptus Therapeutics, Inc.

Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.
Entered $20M equity line with Yorkville in Feb 2025; expects cash runway into Q2 2025.
Phase 1 Decoy20 weekly dosing cohort >20 patients; early stable disease observed.
R&D expense Q4 2024 $2.5M vs $2.0M YoY; full-year $7.2M vs $7.6M.
Clinical supply agreement with BeiGene for tislelizumab combo trial expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.